Table 1

Studies included in the meta-analysis: design, patient, CT acquisition and selection characteristics

Study (ref), publication year, N	Study design	Funding	Location/number of sites	Patients	Type of scanner/ acquisition mode*
PLATFORM, Douglas et al 2016, n=177†18	Multicentre prospective cohort study, CTA and FFR_CT local site read	HeartFlow	Europe/11	Clinically suspected CAD Mean age, 61 years Male gender, 60% Mean pretest likelihood of obstructive CAD, 49% Minimum CTA diameter stenosis ≥30%	Single-source or dual-source CT scanners with a minimum of 64 detector rows/ Prospective ECG triggering or retrospective gating
Aarhus study, Nørgaard et al 2018, n=67717	Single-centre observational registry, CTA and FFR_CT local site read	Investigator-initiated	Denmark/1	Clinically suspected CAD Mean age, 61 years Male gender, 66% Mean pretest likelihood of obstructive CAD, 45% Minimum CTA diameter stenosis ≥30%	Somatom Definition Flash or Force, Siemens/ Prospective ECG triggering
ADVANCE Registry, Patel et al 2020, n=473719	Multicentre prospective registry, CTA and FFR_CT local site read	HeartFlow	Europe, Japan, North America/38	Clinically suspected CAD Mean age, 66 years Male gender, 66% Mean pretest likelihood of obstructive CAD, 62% Minimum CTA diameter stenosis ≥30%	Single-source or dual-source CT scanners with a minimum of 64 detector rows/ Prospective ECG triggering or retrospective gating
NXT, Ihdayhid et al 2019 n=20623	Subanalysis of prospective multicentre study, CTA and FFR_CT core-lab analysis	Investigator-initiated (the original NXT study was funded by HeartFlow, but the follow-up study was performed by investigators independently of HeartFlow).	Europe, Japan, Australia, South Korea/9	Clinically suspected CAD Mean age, 64 years Male gender, 68% Mean pretest likelihood of obstructive CAD, 54% Min CTA diameter stenosis ≥30%	Single-source or dual-source CT scanners with a minimum of 64 detector rows/ Prospective ECG triggering or retrospective gating
Vancouver study, McNabney et al 2019, n=20724	Single-centre observational registry, CTA local site read	Investigator-initiated	Canada/1	Suspected stable CAD Mean age, 62 years Male gender, 76% Mean pretest likelihood of obstructive CAD, information not available Minimum CTA diameter stenosis ≥30%	Either 64-row (Discovery 750HD, GE) or 256-row (Revolution, GE) scanners/ Prospective ECG triggering or retrospective gating

Study (ref), publication year, N	FFR_CT reading point	Proportion of patients with CTA stenosis ≥50 %/FFR_CT≤0.80	Number of patients included in meta-analysis/% relative to the total number of patients in the mother study (reason for exclusion)
PLATFORM, Douglas et al 2016, n=177†18	The lowest per-patient value	51%/39%	177/100%
Aarhus study, Nørgaard et al 2018, n=67717	Two centimetres distal to stenosis in the event of lesion-specific ischaemia, otherwise the lowest per-patient value‡	75%/36%	584/86% (1-year follow-up data were not available in 93 patients)
ADVANCE Registry, Patel et al 2020, n=473719	The lowest per-patient value	72%/66%	4328/91% (1-year follow-up data were not available in 409 patients)
NXT, Ihdayhid et al 2019, n=20623	In a blinded fashion corresponding to the location of the pressure wire (lesion-specific ischaemia)	81%/53%	206/100%
Vancouver study, McNabney et al 2019, n=20724	Two centimetres distal to stenosis (lesion-specific ischaemia)	65%/32%	165/80% (42 patients were included in the ADVANCE Registry)

*Scan acquisition was performed in accordance with the Society of Cardiovascular Computed Tomography (SCCT) best practice guidelines in all studies.
†Only 201 out of the 584 patients included in the study had FFR_CT prescribed, of whom FFR_CT was analysable in 177.
‡For this meta-analysis, the lowest per-patient FFR_CT value was used.
ADVANCE, Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care registry; CAD, coronary artery disease; CTA, CT angiography; FFR_CT, CTA-derived fractional flow reserve; NXT, Analysis of Coronary Blood Flow Using CT Angiography, Next Steps trial ; PLATFORM, Prospective Longitudinal Trial of FFRCT: Outcome and Resource impacts trial.